Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression? by Marco Tafani et al.
REVIEW ARTICLE
published: 12 February 2013
doi: 10.3389/fphar.2013.00013
Modulators of HIF1α and NFkB in cancer treatment: is it a
rational approach for controlling malignant progression?
MarcoTafani 1,2, Bruna Pucci 2, Andrea Russo3, Luana Schito4, Laura Pellegrini 2,5, Giulietta A. Perrone6,
LidiaVillanova2,7, Luisa Salvatori 8, Linda Ravenna8, Elisa Petrangeli 1,8 and Matteo A. Russo1,2*
1 Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
2 Laboratory of Molecular and Cellular Pathology – Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy
3 Department of Surgical Pathology, Istituti di Ricovero e Cura a Carattere Scientifico Istituto Regina Elena, Rome, Italy
4 Vascular Program, Institute of Cellular Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
5 John A. Burns School of Medicine, University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA
6 UOC of Pathologic Anatomy, San Filippo Neri Hospital, Rome, Italy
7 Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University, Stanford, CA, USA
8 Institute of Molecular Biology and Pathology, Consiglio Nazionale delle Ricerche, Rome, Italy
Edited by:
Sarah Crawford, Connecticut State
University, USA
Reviewed by:
Jian Hui Wu, McGill University,
Canada
Hervé Emonard, Centre National de la
Recherche Scientifique, France
*Correspondence:
Matteo A. Russo, Department of
Experimental Medicine, Sapienza
University of Rome, Viale Regina
Elena, 324 – 00161 Roma, Italy.
e-mail: matteoantonio.russo@
uniroma1.it
HIF1α and NFkB are two transcription factors very frequently activated in tumors and
involved in tumor growth, progression, and resistance to chemotherapy. In fact, HIF1α and
NFkB together regulate transcription of over a thousand genes that, in turn, control vital cel-
lular processes such as adaptation to the hypoxia, metabolic reprograming, inflammatory
reparative response, extracellular matrix digestion, migration and invasion, adhesion, etc.
Because of this wide involvement they could control in an integrated manner the origin of
the malignant phenotype. Interestingly, hypoxia and inflammation have been sequentially
bridged in tumors by the discovery that alarmin receptors genes such as RAGE, P2X7, and
some TLRs, are activated by HIF1α; and that, in turn, alarmin receptors strongly activate
NFkB and proinflammatory gene expression, evidencing all the hallmarks of the malignant
phenotype. Recently, a large number of drugs have been identified that inhibit one or both
transcription factors with promising results in terms of controlling tumor progression. In
addition, many of these molecules are natural compounds or off-label drugs already used
to cure other pathologies. Some of them are undergoing clinical trials and soon they will be
used alone or in combination with standard anti-tumoral agents to achieve a better treat-
ment of tumors with reduction of metastasis formation and, more importantly, with a net
increase in survival. This review highlights the central role of HIF1α activated in hypoxic
regions of the tumor, of NFkB activation and proinflammatory gene expression in trans-
formed cells to understand their progression toward malignancy. Different molecules and
strategies to inhibit these transcription factors will be reviewed. Finally, the central role of
a new class of deacetylases called Sirtuins in regulating HIF1α and NFkB activity will be
outlined.
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INTRODUCTION: A NEW PARADIGM ON CANCER
PATHOGENESIS
The currently prevalent theory on cancer pathogenesis still
assumes that the basic events for carcinogenesis and metastasis
are mutations that are accumulated by a single cell during its life.
Although Weinberg demonstrated that a combination of mutated
oncogenes and/or suppressor genes transfected in a normal cell
can produce a fully transformed cell, there is no demonstration
that another set of genes can produce the malignant phenotype,
invading and forming metastasis.
Hanahan and Weinberg (2011) proposed that microenviron-
ment could participate to the progression in many ways: providing
VEGF, cytokines, and other growth and survival factors, mostly
from activated mesenchymal and inflammatory cells; and creating
a reactive oxygen species (ROS)-rich microenvironment which
could favor new mutations.
MUTATIONS FOR TRANSFORMATION
Transformation is characterized by loss of control of proliferation
and/or of apoptosis and it is due to an accumulation of mutations
with gain-of-function (oncogenes) or loss-of-function (oncosup-
pressor genes) of gene families related to the cell cycle control and
apoptosis control (Hanahan and Weinberg, 2011; Larsson, 2011).
Mutations of genes belonging to the DNA repair mechanisms may
be responsible for the upstream steps in this sequence, increasing
the chances of accumulation of the mutations needed to have a
transformed phenotype. Experimental models of transformation
definitely have established the cause/effect relationship between
certain mutations of these genes and the precise generation of a
transformed phenotype (Elenbaas et al., 2001; Ince et al., 2007).
Genomic instability, chemical mutagens, and radiations
are responsible for random mutations that can involve
transformation-related genes. Epigenetic changes (methylation or
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acetylation status of DNA) and alterations in chromatin struc-
ture maintenance mechanisms can stably achieve biological effects
(gain-of-function, loss-of-function) on proliferation and apopto-
sis control, similar to the classical mutations (Huang et al., 2011;
Vanden Berghe, 2012). Mutations can be established in somatic
(stem) cells in any period of life or can be present in the zygote
being inherited from parents. This last type of mutations is respon-
sible for inherited tumor risk and usually regards a loss-of-function
of oncosuppressor genes. A gain-of-function of oncogenes (such
as ret oncogene) can be observed only exceptionally (Traugott and
Moley, 2010). This can be explained by the fact that the presence
of oncogene mutations, disrupting normal morphogenesis and
development, lead to premature embryonic or fetal death.
ADAPTATIONAL RESPONSES FOR PROGRESSION
Progression is characterized by the acquisition of the malignant
phenotype that leads to a clinically significant tumor. Malignancy
includes ability to grow above the limited dimensions conditioned
by diffusion of oxygen and nutrients in the absence of newly
formed vessels (neoangiogenesis), ability to extrude and/or inacti-
vate entire families of molecules (resistance to drugs), invasion of
adjacent tissues (degradation of BM and ECM), ability to detach
from original tissue (changes in adhesive molecules and proper-
ties), to migrate in response to a chemoattractant (receptors for
chemokines and other chemoattractants), to homing in a specific
site that will harbor the new tumor (expression of new sets of
adhesive molecules which will encounter their countereceptors on
an otherwise activated distant endothelium; Furuta et al., 2010;
Zigler et al., 2010; Noman et al., 2011; Nasr and Pelletier, 2012).
Most of these genes have been individually studied and analyzed
for their mutation, epigenetic changes, and other abnormalities to
determine their contributes to the malignancy.
However, the understanding of the progression and all the
properties of a malignant cell in terms of mutations of all the nec-
essary genes, has been disappointing and unrealistic. These genes
are so numerous that the stochastical occurrence of their muta-
tions during the entire human life is statistically improbable or
impossible. Today it is generally accepted that, although mutations
of progression-related genes may contribute to the malignancy,
other factors, not necessarily mutations, are responsible for the
pathogenetic sequence leading to the malignant phenotype.
In the last decade the tissue environment in which the tumor
originate and manifest has been subjected to an intensive study.
Results of this analysis show that microenvironment of both host
tissue and tumor tissue contributes in many ways to the progres-
sion and to the final destination of a tumor. A plethora of papers
have shown that the contribution depends on cell involved,on local
interaction among cells, on paracrine signals generated, on the
level of local hypoxia, on the presence of an active local immune-
inflammatory response with activated leukocytes and on many
other factors (Zigler et al., 2010; Noman et al., 2011; Coleman
et al., 2012; Hanahan and Coussens, 2012; Hao et al., 2012; Mucaj
et al., 2012; Muratori and Tamagnone, 2012; Nasr and Pelletier,
2012).
Among these so many different contributions, it is difficult to
evaluate the precise role of each factor as well as their position
in the pathway originating a malignant tumor. In addition, they
are too heterogeneous to be included in a logical and sequen-
tial pathway in the attempt to fully explain the various facets
of the malignant phenotype. Any available unitary framework,
including the one recently proposed by Hanahan and Weinberg
(2011), is unable to contain all the heterogeneous observations
and experiments.
However, papers from many laboratories converged toward an
unitary explanation of the progression of the early transformed
cells. From one side it has been demonstrated that a great pro-
motion to the malignancy can come from gene adaptation to the
hypoxia (Shay and Celeste Simon, 2012). From the other side it
has been shown that many proinflammatory genes are overex-
pressed by malignant cells (Tafani et al., 2011a,b; Jin et al., 2012;
Schito et al., 2012; Yao et al., 2012; De Santis et al., 2013). Bridg-
ing hypoxia adaptation and proinflammatory gene expression by
cancer cells, we suggested the hypothesis that these two very com-
plex cell responses, when sequentially activated, could be a good
candidate framework to explain all the properties of the malig-
nant phenotype. In addition, we suggested that transformed (still
non-progressed) tumor stem cells could best adapt to generate this
kind of responses.
In the next paragraph we will analyze the molecular and
biological effects of the hypoxia on transformed cancer cells.
HYPOXIA AND INFLAMMATION IN CANCER PROGRESSION.
GENERATION OF A HYPOXIC AND PROINFLAMMATORY
MICROENVIRONMENT IN A GROWING EARLY TUMOR
Early transformed cancer cells are able to proliferate and form small
tumors in the absence of neoangiogenesis. Oxygen and nutrients
can diffuse from host normal tissue vessels over a radius of no
more than 200µm (Brahimi-Horn et al., 2007). When the small
tumor reaches more than 400µm in diameter, a hypoxic environ-
ment is generated, especially in the center of the tumor (Toffoli
and Michiels, 2008).
Hypoxia produces two basic consequences: (a) Necrosis of cells
that are more distant from vessels of host tissue; (b) Activation
of HIF1α in surviving tumor cells closer to the vessels and sub-
lethally damaged; the HIF1α-driven gene expression allows them
to survive and grow increasing their commitment to malignancy
(Figure 1).
Activation of HIF1α leads to the expression of hundreds genes
(Table 1). Many of them provide a first impulse (commitment)
toward tumor progression. VEGFs and their receptors are respon-
sible for neoangiogenesis and for the possibility to grow above
the limit of 400µm in diameter; telomerase activation increases
the proliferative potential and the number of possible cycles;
and changes in intermediate and energy metabolism are the best
known metabolic effects of this adaptation (Brahimi-Horn et al.,
2007; Mucaj et al., 2012).
Necrotic damage include plasma membrane fragmentation
and release of intracellular molecules, some of which constitute
alarmins or Damage-Associated Molecular Patterns (DAMPs).
The interaction of released alarmins with their receptors triggers
a proinflammatory gene expression in various cell types: resident
innate immunity cells or leukocytes, which usually express in their
plasma membrane a number of alarmin receptors and tumor
cells in which alarmin receptors have been induced by hypoxia
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FIGURE 1 | Schematic representation of the pathway linking hypoxia and HIF1α activation with inflammation and tumor progression.
Table 1 | Adaptation to hypoxia in transformed (stem) cells.
Genes and molecules
activated by HIF1α
Biological adaptation toward
malignant phenotype
Reference
1 VRGFs and VEGFRs Neoangiogenesis Ahluwalia and Tarnawski (2012)
2 TERT Increase in telomere length and proliferative potential Guan et al. (2012)
3 c-Myc; cyclin D1 Increased proliferation Fer and Melillo (2011), Zhu et al. (2010)
4 TERT, OCT4, Notch Stem cell renewal Lee et al. (2012), Qiang et al. (2012)
5 ABC transporter Drug resistance Maugeri-Saccà et al. (2011)
6 ALDA, PGK, GLUT-1 Changes in energy metabolism Mucaj et al. (2012), Semenza et al. (1996), Lam et al. (2009)
7 CXCR4. . . Motility Lu and Kang (2010)
8 MMP9 Integrity of basement membrane, invasivity Choi et al. (2011b)
9 Alarmin (DAMPs) receptors NFkB activation; IRR gene expression Tafani et al. (2011a)
(Tafani et al., 2011a). Alarmin receptor signaling leads to the
activation of NFkB and then to the proinflammatory gene expres-
sion. This proinflammatory microenvironment can contribute to
tumor progression (see below).
ON THE ROLE OF HIF1α AND HIF1α-DEPENDENT GENES
By examining the functions of the genes activated by HIF1α it is
evident that a number of these genes or gene families play a crit-
ical role in pushing a transformed cell toward the acquisition of
many hallmarks of malignancy. In particular, the overexpression of
VEGFs and their receptors (Ahluwalia and Tarnawski, 2012) acti-
vate a tumor-specific neoangiogenesis, allowing the early tumor to
grow over the dimensions (200–300µm), imposed by the simple
diffusion of oxygen and nutrients. The activation of telomerase
(TERT) increases the length of telomeres and the proliferative
potential, immortalizing the involved tumor cells (Guan et al.,
2012). A further contribute to the proliferative potential is given by
the HIF1α-dependent activation of typical proproliferative genes
such as c-myc and cyclin D1 (Zhu et al., 2010; Fer and Melillo,
2011). In addition, HIF1α activates OCT4 and Notch facilitat-
ing stem cell renewal, contributing to the immortalization (Lee
et al., 2012; Qiang et al., 2012). Resistance to chemotherapy is
achieved by overexpression of ABC transporters (Maugeri-Saccà
et al., 2011). The overexpression of a number of key-molecules
such as ALDA, PGK, GLUT-1, beautifully explains the reprogram-
ing of the tumor energy metabolism (increased glucose transport
and consumption and high glycolysis with lactate production;
Semenza et al., 1996; Lam et al., 2009; Mucaj et al., 2012).
Most of the invasion and metastasis genes are co-controlled by
HIF1α and by NFkB. Therefore, they will be examined in the next
paragraph.
Finally, more importantly, we have observed that in a hypoxic
environment a number of cell types, including cancer and nor-
mal stem cells, express de novo or overexpress different alarmin
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receptors (similar to those present in activated leukocytes or
CD45+ cells; Tafani et al., 2011a). RAGE, P2X7, TLRs, and others,
upon activation by alarmins released by necrotic cells, converge
in the activation of NFkB with a robust proinflammatory gene
expression (Figure 1). This represents the key event to bridge
the adaptation to the hypoxia with the expression of hundreds
of genes related to the Inflammatory Reparative Response (IRR)
and, very importantly, to the acquisition of classical properties to
the malignant phenotype. Table 1 summarizes genes or gene fam-
ilies principally involved in the hypoxia adaptation contributing
to the malignant progression. This picture include also the so-
called EMT (epithelial-mesenchymal transition), in which all the
involved genes can be HIF1α and/or NFkB-dependent (Micalizzi
et al., 2010).
ON THE ROLE OF NFkB AND NFkB-DEPENDENT GENES
Once NFkB has been activated through many different pathways, a
complex gene response occurs, with the expression of hundreds of
genes belonging to specific gene families including a large number
of members functionally related to the inflammatory and repara-
tive response (see Table 2). Individually most of these genes have
been implicated in the acquisition of crucial properties of the
malignant phenotype, providing a coherent theoretical framework
to explain the acquisition of most of the malignant hallmarks as
an integrated response and adaptation to the tumor environment.
Inducible enzymes (COX2; 5-LOX, iNOS)
Inducible enzymes produced in activated leukocytes upon acti-
vation of NFkB are responsible for mediator molecules produc-
tion such as prostaglandins, leukotrienes, and NO, leading to
the manifestation and amplification of the IRR. Their presence
in tumor microenvironment and their expression by tumor cells
itself has been one of the earliest observation involving inflamma-
tion in the pathogenesis of cancer and its progression (Wang and
Dubois, 2006). Molecules produced by these enzymes contribute
to the many aspects of tumor progression such as neoangiogen-
esis, recruitment of leukocyte to the tumor microenvironment,
and changes for EMT (Micalizzi et al., 2010). Almost 15 years
ago a landmark epidemiological study suggested that the use of
low-dose aspirin for cardiovascular prevention drastically reduced
the risk for colon cancer (Gustafson-Svärd et al., 1997). These
epidemiological observations stimulated a number of other retro-
spective studies and controlled clinical trials on aspirin and other
COX2 inhibitors in preventing tumors and their progression, giv-
ing rise to a new era in the understanding the role of inflammation
in tumor pathogenesis.
Cytokines and their receptors
Cytokines characterizes IRR directly influencing target leukocytes,
polarizing the response as Th1 or Th2 and stimulating the prolif-
eration of target cells (CD45+) to reinforce and amplify the IRR
(DiDonato et al., 2012). Cytokines are present in most human
tumor microenvironment, being produced by cancer cells itself
and/or by leukocyte infiltrate (DiDonato et al., 2012). Interest-
ingly, tumor cells express also receptors for various cytokines in
parallel with their degree of malignancy (DiDonato et al., 2012).
Therefore, thanks to the presence of cytokine receptors, tumor
cells can be strongly influenced in their biology, such as prolifer-
ation rate (IL-2) and in their polarization (Th1 cytokines) and,
probably, in the expression of adhesion molecules and their coun-
tereceptors, thus influencing the homing for metastasis (DiDonato
et al., 2012).
MMPs and TIMPs
MMPs and TIMPs are NFkB-dependent genes normally expressed
in activated leukocytes, but it is well known that disruption of
the MMP/TIMP activity ratio with a gain-of-function of proteasic
activity over basement membrane and extracellular matrix pro-
teins is present in malignant tumors and parallels the invasive
potential (Tobar et al., 2010; Choi et al., 2011b). Then the key
event for demolishing the physiological tissue barrier (limits) and
for invasion to start is basically controlled by both HIF1α and
NFkB through the expression of these genes.
Adhesion molecules and counter-receptors
The activation of NFkB in leukocytes finely reprograms the expres-
sion of adhesion molecules for migration and for homing at
constitutive district tissue or at damaged site. A NFkB-dependent
and/or cytokine-dependent new expression of adhesive mole-
cules occurs also in tumor cells, allowing a number of biological
changes typically related with malignancy. These changes include
the ability to detach from the original tissue (i.e., cadherins),
Table 2 | IRR gene expression and malignant phenotype biological properties.
N IRR gene families
dependent on NFkB
Biological functions leading
to malignant phenotype
Reference
1 MMPs and TIMPs Digestion of basement membrane and ECM; invasion Tobar et al. (2010)
2 Adhesion molecules and counter-receptors Detachment; homing; organ/tissue tropism; metastatic pattern Marcu et al. (2010)
3 Chemokines and their receptors Migration; homing; metastatic patterns Lu and Kang (2010)
4 Inducible enzymes (COX2; iNOS) Extravasation, migration, angiogenesis Wang and Dubois (2006)
5 Cytokines and their receptors Local amplification of IRR, proliferation, and survival DiDonato et al. (2012)
6 VEGFs and VEGFRs Angiogenesis Ono (2008)
7 Growth and survival factors Proliferation; antiapoptosis Langley and Fidler (2011)
8 Acute-phase proteins IRR amplification; chemotaxis; repair; DAMPs Hiratsuka et al. (2008)
9 SOCS Negative regulation of IRR; antimetastatic Strebovsky et al. (2012)
10 Nm23 Cytoskeletal regulation and organization Liu et al. (2011)
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the ability to migrate following a specific chemotactic gradient
and a path of ECM molecules (receptors for chemokines and
integrins), and, finally, the identification of the homing site repre-
sented by activated endothelial cells (ICAM-1, selectins, and their
countereceptors; Marcu et al., 2010).
Chemokines and their receptors
Tumor cells express both chemokines and their receptors in par-
allel with their degree of malignancy (Lu and Kang, 2010). The
production of chemokines give rise to a gradient which is probably
the main responsible for the attraction of leukocytes and mononu-
clear infiltration in advanced tumors (Lu and Kang, 2010). More
importantly, the expression of chemokine receptors is a crucial
event for the occurrence of metastasis. In fact, metastasis is a com-
plex event which include a number of steps with the participation
of hundreds of genes. Detachment from the primary tumor tis-
sue must be followed by a vectorial migration along a chemotactic
gradient, which implies the presence of specific receptors for the
chemoattractant. CXCR4, a receptor for SDF1α, is the best char-
acterized in tumor cells and has been definitely associated with
progression and prediction of metastasis in many human tumors
(Lu and Kang, 2010). Both chemokines and their receptors are
under the control of NFkB.
VEGFs and VEGFRs
The occurrence of a clinically relevant tumor, detectable by the
present imaging techniques, needs to grow at the dimension of
a few mm in diameter and then, by default, it needs a process
of neoangiogenesis, with an adequate expression of VEGFs and
VEGFRs in the tumor microenvironment. VGEFs can be pro-
duced both by activated leukocytes and mesenchymal cells present
in the tumor microenvironment or, more importantly, by tumor
cells themselves under the influence of activated HIF1α and NFkB
(Ono, 2008). In the last case it has been demonstrated that cancer
cells (probably tumor stem cells and progenitors) may express also
VEGFRs, suggesting the possibility that tumor cells can contribute
to the formation of their new vascular tree (Ono, 2008).
Growth and survival factors
HIF1α and NFkB control a number of growth and survival fac-
tors and their receptors. This has been demonstrated in activated
leukocytes (involved in tissue repair) and in hypoxia-activated
tumor cells. This is an additional advantage for tumor growth
and a prerequisite for the establishment of a secondary metastatic
tumor. The “Seed and soil” hypothesis predicts that a favorable
tissue environment is relevant for the occurrence of a metastasis
(Langley and Fidler, 2011). In this case growth and survival fac-
tors can be provided both by activated leukocytes or mesenchymal
cells of the microenvironment and by tumor cells themselves in
which proliferative pathways are already activated (transforming
oncogenes) or in which these genes are overexpressed upon NFkB
activation (Brahimi-Horn et al., 2007).
Acute-phase proteins
Acute-phase proteins have been considered plasma markers use-
ful to evaluate the systemic IRR. They include soluble and cell
bound isoforms, such as C reactive protein, pentraxin-3, and other
pentraxins; their functions are only partially elucidated. Similarly
to the other NFkB-dependent genes, they appear expressed or
overexpressed in hypoxia-activated tumor cells and in activated
leukocytes. Their functions in tumor progression is still debated.
From one side, they appear to inhibit tumor cell proliferation
and to decrease with progression (Ronca et al., submitted), from
the other hand they can be highly expressed in malignant cells
compared to the host normal tissue (Hiratsuka et al., 2008).
SOCS and negative regulators
NFkB activation include also the expression of a number of
negative key-regulator proteins of IRR, such as SOCS-1 (Stre-
bovsky et al., 2012). This latter protein is a member of SOCS
family which suppress the cytokine signaling via JAK/STAT, down-
regulate TLR expression and signaling and decrease the NFkB
activity and duration (Strebovsky et al., 2012). This family and
other negative regulators are considered part of the normal
feed-back control of the IRR. As predicted by our hypothesis,
SOCS-1 decreased in hypoxia-activated cells, as a physiological
response of HIF1α-NFkB integrated activation (De Santis et al.,
2013).
Anti-HIF1α and anti-IRR tumor therapy and cancer prevention
A number of epidemiological studies and some clinical controlled
trials support the idea that the negative modulation of IRR reduces
the risk and the incidence of some tumors and, in addition, may
slow or inhibit their progression toward malignancy. These obser-
vations and the experimental studies linking hypoxia, IRR, and
tumor progression have suggested new strategies for prevent-
ing tumors, reducing their incidence, slowing their progression,
substantially increasing survival, and decreasing death ratio for
malignancy (Liu et al., 2011).
MODULATORS OF HIF AND HIF-DEPENDENT GENES
Recently and because of its central role in tumor progression,
HIF1αhas become the target of an increasing number of inhibitors
developed with the aim to block or reduce tumor growth and
possibly progression (Semenza, 2012; Xia et al., 2012; Figure 2).
However, it must be noted that most of these compounds are
FDA approved molecules used for treatment of cancer or other
pathologies or natural products and that most of the studies and
discoveries on inhibitors or activators of HIF1α have been made
in cell-based systems or xenografts by research laboratories and
not by pharmaceutical companies (Semenza, 2012). Inhibitors
identified so far exert their action through a variety of different
mechanisms ranging from decreased mRNA and protein levels of
HIF1α, to prevention of HIF1α dimerization or DNA binding, to
inhibition of HIF1α binding to co-activators. Some representa-
tive compounds acting at different steps of HIF1α pathway are
reported on Figure 3.
SEVERAL COMPOUNDS HAVE BEEN SHOWN TO REDUCE HIF1α
PROTEIN AND mRNA ACCUMULATION
Among those: (1) PI3Kinase inhibitors wortmannin and LY294002
as well as mTOR inhibitor rapamycin have been shown to reduce
HIF1α protein levels in different cell lines (Jiang et al., 2001;
Majumder et al., 2004). In fact, these studies demonstrate that
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FIGURE 2 | HIF1α activation can be inhibited at different steps along the pathway.
the rapamycin-sensitive functions of mTOR are not essential for
the accumulation of HIF1α but are important for full expression
of this protein as well as for integrating oxygen and nutrient poor
conditions (Majumder et al., 2004). (2) Inhibition of HIF1α pro-
tein expression and decreased growth of tumor xenografts has been
obtained also with cardiac glycosides such as digoxin, ouabain, etc
(Semenza, 2012). Digoxin has been used for treatment of heart dis-
ease for a long time and it is therefore of particular interest for a
combinatorial therapy with other conventional anti-tumor agents
(Zhang et al., 2008). (3) Microtubule targeting agents such as 2
methoxyestradiol (2ME2) and its synthetic derivatives prevents
HIF1α translation and nuclear accumulation with a correspond-
ing anti-tumor activity (Mabjeesh et al., 2003). However, the exact
mechanism of action of such compounds has not been fully elu-
cidated. (4) Class II histone deacetylase (HDAC) inhibitors such
as trichostatin and LAQ824 increased HIF1α ubiquitination and
degradation of HIF1α by an unknown mechanism (Qian et al.,
2006). The emerging role of class III HDAC on HIF1α stabiliza-
tion will be discussed in detail below. (5) Locked nucleic acid
(LNA)-based oligonucleotides are third generation of antisense
technology that offer high stability and long lasting target inhibi-
tion. EZN-2968 is a LNA directed against HIF1α that has shown
great inhibition of HIF1α and HIF1α-dependent genes and that
is currently under phase I clinical study because of its ability to
reduce tumor growth in xenografts (Greenberger et al., 2008). (6)
Ibuprofen and other NSAIDs decreased HIF1α and HIF2α protein
levels in prostate cancer cells by a yet to define mechanism that
could involve either the PI3K or the proteasome (Palayoor et al.,
2003). However, HIF degradation by ibuprofen was not due to its
COX2 inhibition activity (Isaacs et al., 2002). (7) Natural antibi-
otic geldanamycin (GA) and antifungal radicicol prevent binding
of Hsp90 to HIF1α thereby decreasing its stability with subse-
quent proteasomal degradation (Isaacs et al., 2002). In particular,
derivates of GA are now in clinical trials. Similarly,Antimycin A, an
antibiotic from Streptomyces sp. that induces apoptosis and inhibits
the mitochondrial electron transport chain from cytochrome b to
cytochrome C1, decreased HIF1α protein level by an unknown
mechanism (Maeda et al., 2006). (8) A plethora of natural prod-
ucts possess inhibitory effects of HIF1α. Many of these substances
increase HIF1α degradation by activating proteasomal system or
by unknown mechanisms. In particular, moracin O and P derived
from Morus species (mulberry bark) activates HIF1α degrada-
tion (Dat et al., 2009). Other HIF1α inhibitors are manassantin
B from the aquatic plant Saururus cernus that probably exerts its
effect by degrading HIF1α and inhibiting VEGF secretion (Hos-
sain et al., 2005). Curcumin and berberine, derived respectively
from the Indian spice turmeric and from the chinese goldthread
increases HIF1α proteasomal degradation (Choi et al., 2006). Sim-
ilar results were obtained with resveratrol, a compound found
in grapes and other plants, and with flavonoids such as methy-
lalpinumisoflavone from the tropical legumaceous Lonchocarpus
glabrescens (Park et al., 2007; Liu et al., 2009). Sibiriquinone A
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs February 2013 | Volume 4 | Article 13 | 6
Tafani et al. HIF1α/NFkB modulation in tumor progression
FIGURE 3 | Selection of compounds that can be used to modulate
HIF1α pathway.
from red sage suppressed HIF1α accumulation and VEGF secre-
tion through HIF1α degradation (Dat et al., 2007). This partial
list clearly demonstrates that natural products are an important
source of HIF1α inhibitors that act through a variety of different
mechanisms many of which still unknown.
INHIBITION OF HIF1α DIMERIZATION HAS BEEN DEMONSTRATED BY
TWO COMPOUNDS
Acriflavine and Korean red ginseng. Acriflavine, an antibacter-
ial agent, binds to the PAS-B subdomain of HIF1α and HIF2α
thereby preventing the binding to HIF1β, an effect that results in
reduced VEGF production and tumor growth (Lee et al., 2009).
Water extract of red ginseng inhibited HIF1α and 1β dimerization
with no toxic effects, however, the mechanism of action and the
anti-tumoral effects are not known (Choi et al., 2011a).
DNA BINDING OF HIF TO HREWITH EXPRESSION OF HIF1α-DEPENDENT
GENES HAS BEEN INHIBITED BY SEVERAL COMPOUNDS
Synthetic polyamides binding to and inhibiting HRE elements rec-
ognized by HIF1α prevented VEGF synthesis (Semenza, 2012).
Doxorubicin and daunorubicin bind to DNA and prevent HIF
binding, transcription of target genes, and tumor growth (Tanaka
et al., 2012). Finally, echinomycin, an antibiotic isolated from
Streptomyces echinatus, binds to DNA and inhibits HIF1α activity
(Wang et al., 2011).
HIF1α TRANSCRIPTIONAL ACTIVITY REQUIRES BINDING TO THE
COACTIVATOR p300
Chetomin, a metabolite from the fungus chaetomium, prevents
HIF-p300 binding by acting on p300 structure and inhibit tran-
scription of HIF target genes (Kung et al., 2004). In nude mice,
Chetomin prevented tumor growth without affecting body weight
(Kung et al., 2004). Bortezomib, a proteasome inhibitor, binds to
the domain of HIF1α that interacts with p300 thereby preventing
a functional interaction between these two factors and blocking
transcription of target genes (Befani et al., 2012).
MODULATORS OF NFkB AND NFkB-DEPENDENT GENES
The transcription factor NFkB plays a central role during tumori-
genesis because promotes the expression of more than 500 genes
involved in crucial cellular pathways such as suppression of apop-
tosis, increased migration and invasion, increased digestion of
extracellular matrix, increased expression of adhesion molecules,
etc (Gupta et al., 2010; Figure 4). NFkB is regulated by many
post-translational modifications such as methylation, acetylation,
phosphorylation, ubiquitination. Moreover, once activated, NFkB
translocates and accumulates in the nucleus where binds to the
DNA and activates transcription of a plethora of genes (Gupta
et al., 2010). Therefore, similarly to HIF1α, also NFkB can be
modulated by acting on different steps of the pathways that con-
trols its activity. Again, many natural products mostly with anti-
inflammatory properties are NFkB inhibitors (Gupta et al., 2010).
More than 700 inhibitors of NFkB have been identified so far and
their importance is due to the central role that this transcription
factor has for many pathologies, beside inflammation and cancer
(Wilczynski et al., 2011). Some representative compounds acting
at different steps of NFkB pathway are reported on Figure 5.
Moreover, it is possible to group the large number of NFkB
inhibitors by considering their mechanism of action. In particular:
NFkB REGULATION BY PROTEIN KINASES INHIBITION OR PROTEIN
PHOSPHATASES ACTIVATION
This class of NFkB inhibitors prevents the activation of IKK
kinases. IKK phosphorylates and increases the degradation of the
inhibitory subunit IkB, thereby activating NFkB (Gupta et al.,
2010). However, only for few IKK inhibitors the mechanism of
action is known (Gupta et al., 2010). Among these IKK inhibitors
there are natural compounds such as B-carboline (Karin et al.,
2004), an indole alkaloid extracted from several plants and that
acts as a benzodiazepine agonist, parthenolide, a natural com-
pound isolated from feverfew that acts by interacting with Cys-179
of IKK and, curcumin (Lubbad et al., 2009; Gupta et al., 2010). In
particular, parthenolide seems to have an anti-tumoral activity
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FIGURE 4 | NFkB activation pathway and its different inhibition steps.
also on cancer stem cells (Gunn et al., 2011). Anti-inflammatory
drugs are IKK inhibitors although with an unknown mechanisms
(Wilczynski et al., 2011). Among these there are: aspirin, ibupro-
fen, sulindac, sulfasalazine, and other NSAIDs (Kast, 2006). Other
NFkB inhibitors are some kinase inhibitors such as SB203580,
PD0980589, tyrosine kinase inhibitors, betaine, etc. (Vanden
Berghe et al., 1998). Finally also both IKK dominant negative
kinase delivered by adenoviruses and antibodies anti-IKK are
alternative strategies that could inhibit NFkB activation (Gupta
et al., 2010). By contrast NFkB can be inhibited by activating
phosphatases that reduce IkB phosphorylation. For example, cyto-
sine arabinoside dephosphorylates NFKB and induces apoptosis
in tumor cells (Sreenivasan et al., 2003).
NFkB REGULATION BY PROTEASOME INHIBITION
This strategy exploits the fact that inhibition of IkB degradation
by the proteasomal system, results in inhibition of NFkB. A well
studied and used proteasome inhibitor is Bortezomib (also men-
tioned as HIF1α inhibitor) that has been shown to reduce tumor
growth in xenograft models and has been successfully used in
first-line therapy in combination with other drugs such as cis-
platinum (Wilczynski et al., 2011). Inhibition of HIF1α, VEGF,
and tumor vascularization by Bortezomib are additional benefits
that accompany NFkB inhibition. Other proteasome inhibitors
similar to bortezomib include ALLnL, lactacystine, MG132, etc.
Finally, second-generation proteasome inhibitors are carfilzomib
and salinosporamide that act at nanomolar range, have a lower
toxicity and can be delivered orally (Wilczynski et al., 2011; Kale
and Moore, 2012).
NFkB REGULATION BY ACETYLATION INHIBITION
Similar to phosphorylation by kinases and dephosphorylation by
phosphatases, acetylation/deacetylation by acetyl tranferases and
deacetylases is considered an equally important post translation
modification that control the activity of many proteins (Gray
and Teh, 2001). NFkB has been shown to be acetylated on sev-
eral lysines an event that increase its activation (Kiernan et al.,
2003). Therefore, as discussed in major details in the follow-
ing section, the recent discovery of a new class of deacetylases
named Sirtuins has increased the attention toward the possibility
to control NFkB activity through these enzymes. In fact, sirtu-
ins activation causes an inhibition of NFkB. Similarly, NFkB can
be inhibited by inhibiting acetyl transferases such as p300 and
CREB-binding protein (Chen and Greene, 2004). In fact, gallic
acid from gallnuts or oak bark and anacardic acid have been shown
to inhibit NFkB acetylation and consequent activation (Choi et al.,
2009).
NFkB REGULATION BY INHIBITION OF NUCLEAR ACCUMULATION
This approach is based on the fact that preventing NFkB by
accumulating in the nucleus also prevents its DNA associa-
tion and transcription of target genes. However, such mecha-
nism has been documented only for SN50 a peptide with a
hydrophobic membrane-translocating region and the NLS of
NFkB. SN50 competes with NFkB for the nuclear translocation
machinery thereby preventing NFkB nuclear translocation. Unfor-
tunately, SN50 prevents nuclear accumulation of a large number
of transcription factors (Sun et al., 2012). A more promising
inhibitor is a compound derived from a fungal antibiotic called
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FIGURE 5 | Selection of compounds that can be used to modulate
NFkB pathway.
dehydroxymethylepoxyquinomicin (DHMEQ) that specifically
inhibits NFkB nuclear accumulation with anti-inflammatory and
anti-tumoral activity (Kozakai et al., 2012).
SIRTUINS AND SIRT1 ACTIVATORS IN MODULATING HIF1α
AND NFKB
Sirtuins owe their name to silent information regulator 2
(Sir2), identified in yeast and linked to lifespan extension
(Houtkooper et al., 2012). In mammals there are seven Sir2
homologs (SIRTs 1-7). Sirtuins are either class III nicotinamide
adenine dinucleotide-(NAD+)-dependent deacetylase or ADP-
ribosyl transferases (Houtkooper et al., 2012). Their dependence
from NAD+ directly links sirtuins activity to the metabolic state
of the cells. For this reason sirtuins have been implicated in many
physiological functions such as gene silencing, cell death, longevity,
inflammation, and cancer (Houtkooper et al., 2012).
Sirtuins have also shown to associate, deacetylate, and regulate
the activity of both HIF1α and NFkB. However, only for SIRT1, 2,
3, and 6 this regulatory function as been demonstrated.
SIRT1 deacetylates both HIF1α and NFkB. In the case of NFkB
all the results so far point toward an inhibition of its signaling
following deacetylation by SIRT1 (Morris, 2012). In fact, both
in vitro and in vivo experiments have shown that SIRT1 or acti-
vation of SIRT1 by resveratrol and other polyphenols decreases
inflammatory response by deacetylating and inhibiting NFkB.
These results are particularly interesting considering the central
role of NFkB in many cellular pathways involved in inflamma-
tion, aging, cancer, etc. Controversial results have been reported,
instead, for SIRT1/HIF1α signaling. In fact, it is not yet clear if
SIRT1 is influenced or not by hypoxia. Some reports indicates
that hypoxia increases SIRT1 levels whereas others that hypoxia
decreases SIRT1 (Lim et al., 2010; Laemmle et al., 2012). Under
hypoxia SIRT1 deacylates HIF1α however, such reaction in some
cases decreases HIF1α activity, whereas in other increases HIF1α
activity. Obviously, more data must by accumulated on different
cell lines, tissue and in vivo models before the real function of
SIRT1 on HIF1α can be delineated. Moreover, it is also possible
that SIRT1 action of HIF1α differs in different tissues and organs.
SIRT6 is another nuclear sirtuin that controls both HIF1α
and NFkB acetylation status and transcriptional activity. In the
case of HIF1α, SIRT6 functions as a corepressor of HIF1α tran-
scriptional activity, deacetylating histone 3 lysine 8 (H3K9) at
HIF1α target gene promoters. In fact, regulation of glucose flux
by SIRT6 appears critical because SIRT6 deficiency causes a lethal
hypoglycemia (Zhong et al., 2010). Interestingly, a similar mech-
anism is used by SIRT6 to inhibit NFkB function. Also in this
case SIRT6 deacetylates H3K9 on the promoter of selected NFkB
target genes thereby decreasing accessibility to NFkB to these
promoters (Kawahara et al., 2009). Importantly, in SIRT1 defi-
cient mice, SIRT6 has shown a compensatory effect by attenuating
the increased NFkB activity due to an increased acetylation state
(Schug et al., 2010). In conclusion both SIRT1 and SIRT6, although
with different mechanisms, represent negative regulators of NFkB
activity.
SIRT2 has been shown to deacetylate subunit p65 of NFkB
on lysine 310 (K310) in the cytoplasm (Rothgiesser et al., 2010).
In this way SIRT2 inhibits NFkB activation and transcription of
NFkB target genes following TNF stimulation (Rothgiesser et al.,
2010). In fact, SIRT2 silenced cells have an increased activation of
NFkB and a lower percentage of cell death following TNF exposure
(Rothgiesser et al., 2010). Therefore, NFkB can be deacetylated by
SIRT2 in the cytosol and by SIRT1 in the nucleus.
SIRT3 controls HIF1α activation indirectly. In fact, SIRT3
reduces mitochondrial ROS and activates cellular pathways and
enzymes scavenging ROS (Finley et al., 2011; Pellegrini et al.,
2012). In particular, by decreasing ROS levels, SIRT3 stabilizes
HIF degrading enzyme prolyl hydroxylase (PHD) lowering HIF1α
levels (Finley et al., 2011). Interestingly, SIRT3 deficiency is asso-
ciated with tumor growth in xenografts and SIRT3 expression is
lowered in several cancers and cancer cell lines (Finley et al., 2011).
Giving the fact that sirtuins regulates both HIF1α and NFkB
and the central role that these two transcription factors have dur-
ing tumor progression, the possibility to act on sirtuins in order to
control HIF1α and NFkB has drawn much attention. Therefore,
presently, a great deal of efforts have been put in producing Sir-
tuins modulators. Several natural compounds such as resveratrol,
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quercetin, piceatannol, and other polyphenols have been shown to
modulate sirtuins function and particularly SIRT1 (Chung et al.,
2010; Gertz et al., 2012). However, their action is not limited to
SIRT1 but influences other enzymes such as phosphodiesterases
(PDEs) and AMP kinase (AMPK; Dallas et al., 2008). An up-to-
date and accurate review of inhibitors and activators of sirtuins
has been recently published (Villalba and Alcaín, 2012).
ONGOING CLINICAL TRIALS AND FUTURE DIRECTIONS
HIF1α
The recognition of the central role of HIF in tumor growth and
progression and the in vitro and in vivo demonstration of tumor
growth inhibition by many HIF1α inhibitors, is currently trans-
lating in clinical trials for some of them. In particular, 2ME2 is
undergoing Phase II clinical trials in patients with breast, prostate,
and ovarian cancer (Semenza, 2012; Xia et al., 2012). Similarly
also molecules derived from 2ME2 have been selected for evalu-
ation of Phase I clinical trials (Semenza, 2012; Xia et al., 2012).
Analogs of geldanamycin (GA) are in Phase II clinical trials in
patients with VHL disease, breast cancer, etc (Semenza, 2012; Xia
et al., 2012). Bortezomib (velcade) has been approved in the US by
FDA for use in multiple myeloma, based on the results from the
Phase II trial. Two open-label, Phase III trials established the effi-
cacy of bortezomib 1.3 mg/m2 (with or without dexamethasone)
in patients with relapsed/refractory multiple myeloma (Semenza,
2012; Xia et al., 2012). EZN-2968, is currently in Phase I clinical
trials (Semenza, 2012; Xia et al., 2012).
Finally, an important consideration is that many of HIF1α
interacting drugs are in clinical cancer trials or are already
approved for the treatment of cancer or other diseases (Xia et al.,
2012).
NFKB
Several classes of NFkB inhibitors are currently being tested in
conjunction with chemotherapy and radiotherapy. In fact, a large
number of clinical trials are testing the efficacy and specificity of
rationally designed drugs that inhibit NFkB (for a specific trial
in the US see the NIH service at: ClincalTrials.gov). In the case
of NFkB for example the proteasome inhibitor Bortezomib (also
used to inhibit HIF1α) has surprisingly limited side effects and
therefore currently appears to be no reason to reject NFκB as
drug target on the basis of potential adverse effects which might
be induced by inhibition of this transcription factor (Wilczynski
et al., 2011). Recently, in a phase II clinical trial, curcumin was
found to be beneficial for patient with advanced pancreatic cancer
(Wilczynski et al., 2011; Grynkiewicz and Slifirski, 2012). These
are only two examples of a large number of NFkB inhibitors that
are being currently tested. Hopefully, in the next few years sev-
eral NFkB inhibitors that can increase the therapeutic efficiency of
chemotherapy and radiotherapy will be successfully employed in
treatment of cancer patients.
SIRTUINS
Considering the relatively short time that these enzymes are under
investigation, very few sirtuin modulators are under trials. In fact,
currently, there are no modulators that can specifically regulate a
single sirtuin. However, resveratrol and a number of its deriva-
tives have shown beneficial effects on a randomized double-blind
cross-over trials in humans with effects similar to calorie restric-
tion and activation of AMPK, SIRT1, and PGC-1α levels (Timmers
et al., 2011). Inhibitors of SIRT1 and SIRT2 have been proposed for
treatment of cancer but are far from clinical trials (Morris, 2012).
CONCLUSION
Considering the central role of HIF1α and NFkB in metabolic
reprogramming, inflammation, and cancer, and considering also
the fact that both transcription factors are regulated by sirtuins,
the possibility to develop more specific modulators acting on dif-
ferent steps of these molecular net, hold promising results toward
new therapies with higher success rates.
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